2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2011
Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O’Brien E, Jane JS, Dwan R, Dean E, Edens E, Arnaout B, Keegan K, Drew S, Petrakis I. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2011, 7: 64-73. PMID: 26954912, DOI: 10.1080/15504263.2011.569440.Peer-Reviewed Original ResearchEfficacy of acamprosateAlcohol dependenceSchizophrenia spectrum disordersMedication treatmentComorbid schizophreniaSignificant group x time interactionGroup x time interactionComorbid alcohol dependenceAlcohol use disorderSymptoms of schizophreniaX time interactionAcamprosate groupComorbid conditionsTreatment trialsAbstinent patientsClinical trialsSpectrum disorderAcamprosateGeneral populationUse disordersPatientsSchizoaffective disorderPositive symptomsSchizophrenic symptomsConsecutive days